Table 1.
Demographic, Clinical, and Resistance Profiles for Patients With Integrase Resistance Testing
| Patient | Age | RAL/DTG Exposure | Time on INSTIs (Months) | ART Regimen at Time of HIVDR Testing | HIVVL (Copies/mL) | RAL | EVG | DTG | ATV/r | DRV/r | LPV/r |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 52 | RAL | 24 | ABC-3TC-DRV/r-RAL | 2430 | HLR | HLR | HLR | HLR | IR | HLR |
| 25 | 35 | RAL | 60 | LPV/r-RAL | 23 233 | HLR | HLR | IR | IR | S | IR |
| 1 | 17 | RAL | 25 | TDF-FTC-DRV/r-ETR-RAL | 3459 | HLR | HLR | S | IR | IR | HLR |
| 14 | 43 | RAL | 48 | TDF-3TC-RAL | 3070 | HLR | HLR | S | IR | IR | HLR |
| 11 | 52 | RAL | 69 | DRV/r-RAL | 270 252 | HLR | HLR | S | NA | NA | NA |
| 6 | 51 | RAL | 36 | TDF-3TC-DRV/r-RAL | 27 500 | HLR | HLR | S | HLR | IR | HLR |
| 26 | 46 | RAL | Unknown | LPV/r-RAL | 2316 | HLR | HLR | S | S | S | S |
| 4 | 31 | RAL | 5 | d4T-3TC-DRV/r-RAL | 58 200 | HLR | HLR | S | HLR | IR | HLR |
| 12 | 43 | RAL | 12 | TDF-3TC-DRV/r-RAL | 159 000 | HLR | HLR | S | IR | IR | HLR |
| 10 | 61 | RAL | 20 | 3TC-LPV/r-RAL | 92 800 | HLR | HLR | S | HLR | S | HLR |
| 16 | 45 | RAL | 32 | TDF-FTC-DRV/r-RAL | 13 000 | HLR | HLR | S | S | S | S |
| 42 | 12 | RAL | Unknown | ABC-3TC-DRV/r-RAL | 1843 | HLR | IR | S | HLR | IR | HLR |
| 18 | 44 | RAL | 23 | TDF-3TC-RAL | 778 000 | HLR | IR | S | S | S | S |
| 2 | 47 | RAL | 18 | TDF-3TC-DRV/r-RAL | 27 727 | HLR | IR | S | HLR | S | HLR |
| 7 | 20 | RAL | 22 | LPV/r-RAL | 211 000 | HLR | IR | S | HLR | IR | HLR |
| 27 | 51 | RAL | 25 | TDF-LPV/r-RAL | 1 030 000 | HLR | IR | S | IR | IR | HLR |
| 13 | 35 | RAL | 34 | ETR- RAL-DRV/r | 190 000 | HLR | IR | S | HLR | IR | HLR |
| 32 | 52 | RAL | Unknown | AZT-3TC-DRV/r-RAL | 7190 | HLR | IR | S | HLR | HLR | HLR |
| 43 | 45 | RAL | Unknown | AZT-3TC-RAL | 159 000 | HLR | IR | S | HLR | S | S |
| 40 | 34 | RAL | Unknown | AZT-3TC-RAL | 67 816 | HLR | S | S | S | S | S |
| 24a | 45 | RAL | 3 | AZT-3TC-LPV/r(AZT-LPV/r-RAL) | 2520 | S | S | S | S | S | S |
| 37 | 35 | RAL | Unknown | ETR-DRV/r-RAL | 9337 | S | S | S | S | S | S |
| 29 | 14 | RAL | 13 | AZT-3TC-DRV/r-RAL | 42 900 | S | S | S | S | S | S |
| 5a | 58 | RAL | 25 | ABC-3TC-ATZ/r(TDF-3TC-RAL-DRV/r) | 386 000 | S | S | S | S | S | S |
| 28 | 18 | RAL | 27 | AZT-3TC-DRV/r-RAL | 1140 | S | S | S | S | S | S |
| 17 | 39 | RAL | 33 | ABC-TDF-3TC-DRV/r-RAL | 64 200 | S | S | S | IR | IR | HLR |
| 19 | 54 | RAL | 42 | TDF-FTC-DRV/r-RAL | 140 714 | S | S | S | HLR | IR | HLR |
| 22 | 37 | RAL | 53 | AZT-3TC-TDF-DRV/r-RAL | 6990 | S | S | S | HLR | HLR | HLR |
| 31a | 50 | RAL | 70 | ABC-3TC-LPV/r(TDF-FTC-LPV/r-RAL) | 1 370 000 | S | S | S | HLR | IR | HLR |
| 20 | 21 | RAL | Unknown | TDF-3TC-ETR-DRV/r-RAL | 14 900 | S | S | S | S | S | S |
| 41 | 16 | RAL | Unknown | 3TC-DRV/r-RAL | 30 663 | S | S | S | NA | NA | NA |
| 33 | 12 | RAL | Unknown | ETR-DRV/r-RAL | 2530 | S | S | S | HLR | IR | HLR |
| 34 | 10 | RAL | Unknown | AZT-3TC-DRV/r-RAL | 868 | S | S | S | IR | S | IR |
| 38 | 3 | RAL | Unknown | ABC-3TC-LPV/r-RAL | 88 821 | S | S | S | S | S | S |
| 8 | 38 | DTG | 22 | TDF-3TC-DRV/r-DTG | 311 000 | HLR | HLR | IR | IR | IR | HLR |
| 15 | 45 | DTG | 4 | TDF-3TC-DRV/r-DTG | 39 400 | S | S | S | IR | IR | HLR |
| 30 | 43 | DTG | 10 | AZT-3TC-DTG | 6500 | S | S | S | S | S | S |
| 39 | 31 | DTG | 1 | ABC-3TC-ATV/r-DTG | 117 274 | S | S | S | S | S | S |
| 35 | 55 | Unknown | Unknown | Unknown | 429 241 | HLR | IR | S | HLR | HLR | HLR |
| 3 | 57 | Unknown | Unknown | AZT-EFV-LPV/r | 222 604 | S | S | S | S | S | S |
| 21 | 5 | Unknown | Unknown | Unknown | 6990 | S | S | S | IR | S | IR |
| 23 | 41 | Unknown | Unknown | AZT-3TC-LPV/r | 19 400 | S | S | S | IR | S | HLR |
| 36 | 39 | Unknown | Unknown | TDF-FTC-DRV/r | 139 609 | S | S | S | HLR | IR | HLR |
Abbreviations: ABC, abacavir; ART, antiretroviral treatment; ATV/r, ritonavir-boosted atazanavir; AZT, zidovudine; d4T, stavudine; DTG, dolutegravir; DRV/r, ritonavir-boosted darunavir; ETR, etravirine; EVG, elvitegravir; FTC, emtricitabine; HIV, human immunodeficiency virus; HIVDR, HIV drug resistance; HIVVL, HIV viral load; HLR, high-level resistance; INSTIs, integrase strand transfer inhibitors; IR, intermediate resistance; LPV/r, ritonavir-boosted lopinavir; NA, not applicable, no protease and reverse-transcriptase genotype available; RAL, raltegravir; S, susceptible; TDF, tenofovir; 3TC, lamivudine.
aThree patients were not receiving an INSTI at time of genotyping, but their previous regimen (in italics) indicate exposure to INSTI.